Ziccum AB (publ) (ZICC.ST)
SEK 0.25
(0.0%)
SEK 0.25
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 27.87 Million SEK | -12.6% |
| 2022 | 28.95 Million SEK | 37.12% |
| 2021 | 21.11 Million SEK | 22.52% |
| 2020 | 17.23 Million SEK | 97.63% |
| 2019 | 8.72 Million SEK | 96.51% |
| 2018 | 4.43 Million SEK | 1500.24% |
| 2017 | 277.33 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 6.2 Million SEK | -19.19% |
| 2024 Q1 | 6.91 Million SEK | -19.86% |
| 2024 Q2 | 7.67 Million SEK | 11.1% |
| 2023 FY | 25.3 Million SEK | -12.6% |
| 2023 Q3 | 5.58 Million SEK | -9.83% |
| 2023 Q2 | 6.19 Million SEK | 25.57% |
| 2023 Q1 | 4.93 Million SEK | -38.81% |
| 2023 Q4 | 8.62 Million SEK | 54.27% |
| 2022 Q1 | 6.34 Million SEK | -2.05% |
| 2022 FY | 28.95 Million SEK | 37.12% |
| 2022 Q4 | 8.06 Million SEK | 20.87% |
| 2022 Q3 | 6.67 Million SEK | -15.23% |
| 2022 Q2 | 7.87 Million SEK | 24.18% |
| 2021 Q4 | 6.47 Million SEK | 28.31% |
| 2021 Q3 | 5.04 Million SEK | -3.2% |
| 2021 Q2 | 5.21 Million SEK | 18.81% |
| 2021 Q1 | 4.38 Million SEK | 35.86% |
| 2021 FY | 21.11 Million SEK | 22.52% |
| 2020 FY | 17.23 Million SEK | 97.63% |
| 2020 Q3 | 5.31 Million SEK | 12.91% |
| 2020 Q4 | 3.22 Million SEK | -39.27% |
| 2020 Q2 | 4.7 Million SEK | 18.32% |
| 2020 Q1 | 3.98 Million SEK | 19.05% |
| 2019 Q4 | 3.34 Million SEK | 142.25% |
| 2019 Q3 | 1.38 Million SEK | -39.9% |
| 2019 Q2 | 2.29 Million SEK | 35.94% |
| 2019 Q1 | 1.68 Million SEK | -6.37% |
| 2019 FY | 8.72 Million SEK | 96.51% |
| 2018 Q1 | 327 Thousand SEK | 395.45% |
| 2018 Q2 | 575 Thousand SEK | 75.84% |
| 2018 FY | 4.43 Million SEK | 1500.24% |
| 2018 Q4 | 1.8 Million SEK | 5.25% |
| 2018 Q3 | 1.71 Million SEK | 198.09% |
| 2017 Q2 | 104 Thousand SEK | 0.0% |
| 2017 FY | 277.33 Thousand SEK | 0.0% |
| 2017 Q4 | 66 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.159% |
| AcouSort AB (publ) | 25.87 Million SEK | -7.737% |
| Active Biotech AB (publ) | 44.8 Million SEK | 37.785% |
| Alzinova AB (publ) | 36.39 Million SEK | 23.404% |
| Amniotics AB (publ) | 29.07 Million SEK | 4.107% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -90.255% |
| BioArctic AB (publ) | 89.62 Million SEK | 68.896% |
| Camurus AB (publ) | 1.05 Billion SEK | 97.369% |
| Cantargia AB (publ) | 290.01 Million SEK | 90.387% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -27.326% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 1.583% |
| Genovis AB (publ.) | 88.19 Million SEK | 68.391% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 75.774% |
| Mendus AB (publ) | 129.13 Million SEK | 78.412% |
| Kancera AB (publ) | 63.07 Million SEK | 55.803% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -405.128% |
| LIDDS AB (publ) | 27.75 Million SEK | -0.454% |
| Lipum AB (publ) | 37.3 Million SEK | 25.274% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -284.312% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 79.488% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -69.977% |
| NextCell Pharma AB | -576.01 Thousand SEK | 4939.771% |
| OncoZenge AB (publ) | 15.9 Million SEK | -75.278% |
| Saniona AB (publ) | 1.07 Million SEK | -2488.487% |
| Simris Alg AB (publ) | 38.64 Million SEK | 27.856% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 91.329% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 92.205% |
| Xintela AB (publ) | 57.31 Million SEK | 51.361% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -283.572% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 84.66% |
| CombiGene AB (publ) | 44.14 Million SEK | 36.848% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 80.503% |
| Intervacc AB (publ) | 79.78 Million SEK | 65.059% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 90.922% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 34.608% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -57.654% |
| Corline Biomedical AB | 30.16 Million SEK | 7.591% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 51.96% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 66.48% |
| Aptahem AB (publ) | 10.01 Million SEK | -178.42% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 79.303% |
| Fluicell AB (publ) | 28.61 Million SEK | 2.582% |
| Biovica International AB (publ) | 133.72 Million SEK | 79.152% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -40.869% |
| Abliva AB (publ) | 27.86 Million SEK | -0.043% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 85.593% |
| 2cureX AB (publ) | 36.51 Million SEK | 23.66% |
| I-Tech AB | 40.14 Million SEK | 30.562% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 96.756% |
| Cyxone AB (publ) | 28.21 Million SEK | 1.191% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 74.51% |
| Biosergen AB | 26.8 Million SEK | -3.987% |
| Nanologica AB (publ) | 69.88 Million SEK | 60.11% |
| SynAct Pharma AB | 224.49 Million SEK | 87.582% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 36.893% |
| BioInvent International AB (publ) | 441.4 Million SEK | 93.684% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -16.38% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 90.378% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -254.85% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 74.865% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -89.646% |